If I’d invested £1,000 in the Haleon shares spin-off, here’s how much I’d have now

Haleon shares have been public for almost a year but investors remain hawkish over looming legal risks. Zaven Boyrazian investigates further.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Black woman looking concerned while in front of her laptop

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s almost been a year since Haleon (LSE:HLN) shares were spun out from GSK. And while we’re still in the early days, the consumer healthcare company seems to be making solid progress. So let’s take a closer look at what’s been going on since the stock went public.

Off to a good start

Last month, Haleon announced its first-quarter trading results. Despite what the slight dip in valuation would suggest, both sales and profits were up by double-digits.

Total revenue grew by a solid 13.7%, with its Respiratory Health division leading the charge delivering 33% organic growth. Its Vitamins, Minerals and Supplements (VMS) segment sadly shrank by 3.7% year-on-year. However, a closer inspection of the underlying cause reveals some tough comparisons.

In 2022, VMS enjoyed some notable tailwinds from Covid-19 as demand for its Emergen-C tablets shot up in North America. With the pandemic no longer disrupting the world, Emergen-C sales have since normalised.

Over on the profit side of the equation, operating income is up by a chunky 34.5% reaching £627m. However, it’s important to note this boost largely stems from eliminating administrative expenses related to the demerger from GSK. Ignoring these effects, underlying earnings were up by just 9.5%.

That’s far from terrible. But with the currency exchange rate fluctuating, the group couldn’t maintain margins resulting in adjusted operating profitability dropping by 0.9% to 23.1%.

Nevertheless, management remains confident of hitting the higher end of its previously issued 4-6% organic revenue growth guidance, as well as staying on track with its projected earnings. So how have Haleon shares reacted to all this?

Haleon share price performance

While the financials appear to be moving in the right direction, there’s still a lot of work to be done. And it seems other investors share this opinion when looking at how the stock has performed since going public last year.

Haleon shares are up a not-so-grand total of just 2%. That’s nearly half of what the FTSE 100 has delivered before considering dividends.

At an opening price of 330p in July 2022, investing £1,000 into the stock would have fetched approximately 303 shares. Combining the 2.4p dividend per share paid earlier this year with the 2% price gain, the investment would currently be worth around £1,027.27.

Those are hardly the most exciting returns out there. But after a year of independence, the management team has had some time to demonstrate its skill. And while it has yet to be reflected through investment gains, the business seems to be on track.

Having said that, I’m still on the sidelines. Several question marks remain unanswered, the biggest of which is the ongoing litigation surrounding Zantac. Allegations have been made that the drug causes cancer, and while out-of-court settlements are being made, there remains the risk of severe legal penalties. And if Haleon becomes exposed to these penalties, it could easily undo the progress made so far..

Therefore, I’m not tempted to add any Haleon shares to my portfolio today. But I will be keeping a close eye on how the situation develops.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smart young brown businesswoman working from home on a laptop
Investing Articles

5.7% dividend yield! 2 dirt cheap passive income shares to consider in June

These passive income shares are on sale! With low P/E ratios and big dividend yields, Royston Wild says they could…

Read more »

Young woman holding up three fingers
Investing Articles

7% dividend yield! 3 small-cap dividend shares that could deliver a £1,400 second income

These small-cap shares offer bigger dividend yields than most FTSE 100 and FTSE 250 stocks! Here's why I'd buy them…

Read more »

Investing Articles

Lloyds shares look like a brilliant bargain! But are they an investor trap?

Lloyds Banking Group shares have become brilliantly popular in recent weeks. But there are some hidden nasties investors need to…

Read more »

Investing Articles

Is JD Sports still a value share in disguise?

Ahead of its full year results, Christopher Ruane explains why he thinks that despite a rising stock price, JD Sports…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Is this one of the best UK shares for me to buy for growth and returns?

On the hunt for quality UK shares to boost her wealth, has our writer come across an opportunity she can't…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

How I’d try to become a Stocks and Shares ISA millionaire, starting today

There were more than 4,000 Stocks and Shares ISA millionaires in the UK at the last count. Here's how we…

Read more »

Investing Articles

2 magnificent cheap shares investors should consider buying

I’m convinced that there are some excellent cheap shares available on the UK stock market. Here are two to consider!

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

I’d buy 19 shares a week of this FTSE 100 stock to target £200 in annual passive income

Our writer explains how he would try to build an ongoing passive income stream by buying a well-known FTSE 100…

Read more »